SCHEMBL44355

SCHEMBL44355

C#CCOC(=O)CN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycine SCHEMBL9114763 0.93 GLRA1 (0.43)
Trifluoroacetic Acid SCHEMBL9618064 0.86 GSTP1 (0.35)
SCHEMBL13314209 0.81
SCHEMBL10527889 0.79 NPC1 (0.45)
SCHEMBL4446043 0.79 GSTP1 (0.53)
SCHEMBL10010450 0.79
SCHEMBL14613083 0.78 CYP1A2 (0.55)
SCHEMBL4673059 0.77
SCHEMBL4673055 0.77
SCHEMBL9524131 0.76 MGAM (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 565 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4211146-B1 SYNTHETIC CYCLIC PEPTIDE MIMETICS UNIV BAR ILAN (IL) 2026-05-20 EP claimed
US-12616760-B2 Synthetic cyclic peptide mimetics BAR ILAN UNIVERSITY (IL) 2026-05-05 US claimed
US-20260097138-A1 BIOMATERIAL COATED NANOSTRUCTURES FOR PHOTOACOUSTIC IMAGING AND PHOTOTHERMAL THERAPY OF TUMOR LESIONS OSPEDALE SAN RAFFAELE S.R.L. (IT) 2026-04-09 US claimed
US-20250222146-A1 Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof RAYZEBIO, INC. (US) 2025-07-10 US claimed
WO-2025137441-A1 RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF RAYZEBIO, INC. (US) 2025-06-26 WO claimed
US-20250123298-A1 METHODS, SYSTEMS AND COMPOSITIONS FOR THE PREDICTION AND PREVENTION OF PARENTERAL NUTRITION ASSOCIATED CHOLESTASIS USING FECAL BIOMARKERS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2025-04-17 US claimed
US-20250084051-A1 glycerylphosphorylethanolamine (GPE) compound and lipid nanoparticle (LNP)-based drug carrier with same SHANDONG ACADEMY OF PHARMACEUTICAL SCIENCES (CN) 2025-03-13 US claimed
US-20240424137-A1 Biomarkers For Lysosomal Storage Diseases AMICUS THERAPEUTICS, INC. (US) 2024-12-26 US claimed
CN-118813600-A Preparation and application of carrier-free co-immobilized phenylalanine dehydrogenase and formate dehydrogenase 天津科技大学 2024-10-22 CN claimed
US-20240316225-A1 SYNTHETIC CYCLIC PEPTIDE MIMETICS BAR ILAN UNIVERSITY (IL) 2024-09-26 US claimed
EP-2566494-A2 CXCR4 RECEPTOR COMPOUNDS Anchor Therapeutics, Inc. (US) 2013-03-13 EP claimed
US-20130005944-A1 CXCR4 Receptor Compounds ACER THERAPEUTICS INC. 2013-01-03 US claimed
WO-2013001451-A1 VECTOR FOR THE RELEASE OF AN ACTIVE AGENT WHICH IS PHOTOCLEAVABLE BY IRRADIATION IN THE VISIBLE FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2013-01-03 WO claimed
WO-2012173762-A1 CYCLIC LACTADHERIN PEPTIDE MIMETICS AND THEIR USES TRUSTEES OF BOSTON COLLEGE (US) 2012-12-20 WO claimed
WO-2012032181-A2 NOVEL ANTIBODY DERIVATIVES ALLOZYNE, INC (US) 2012-03-15 WO claimed
EP-1809280-B1 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC (US) 2011-09-07 EP claimed
WO-2011106703-A2 CXCR4 RECEPTOR COMPOUNDS ANCHOR THERAPEUTICS, INC. (US) 2011-09-01 WO claimed
EP-0671931-A4 HEMOREGULATORY PEPTIDES. SMITHKLINE BEECHAM CORP (US) 1995-11-22 EP claimed
EP-0671931-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1995-09-20 EP claimed
WO-1993010807-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1993-06-10 WO claimed